Literature DB >> 19234192

An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses.

Claude Haan1, Daniela C Kroy, Stefan Wüller, Ulrike Sommer, Tanja Nöcker, Catherine Rolvering, Iris Behrmann, Peter C Heinrich, Serge Haan.   

Abstract

The Janus kinases, Jaks, constitutively associate with the cytoplasmic region of cytokine receptors and play an important role in a multitude of biological processes. Jak2 dysfunction has been implicated in myeloproliferative diseases and leukemia. Although Jaks were studied extensively for many years, the molecular mechanism of Jak activation upon cytokine stimulation of cells is still incompletely understood. In this study, we investigated the importance of an unusual insertion located within the kinase domain in Jak2. We found that the deletion of this insertion, which we named the Jak-specific insertion (JSI), totally abrogates Jak2 autophosphorylation. We further point mutated four residues within the JSI that are conserved in all Jak family members. Three of these mutants showed abrogated or reduced autophosphorylation, whereas the fourth displayed increased autophosphorylation. We found that the phosphorylation state of these mutants is not influenced by other domains of the kinase. Our data further suggest that the JSI is not required for the negative regulation of kinase activity by the suppressor of cytokine signaling proteins, SOCS. Most importantly, we show that mutations in this region differentially affect IFN-gamma and erythropoietin signal transduction. Taken together, the dramatic effects on the phosphorylation status of Jak2 as well as the differential effects on the signaling via different cytokines highlight the importance of this unusual region for the catalytic activity of Jaks.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19234192     DOI: 10.4049/jimmunol.0800572

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Bobin George Abraham; Heidi Peussa; Stevan R Hubbard; Olli Silvennoinen
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

2.  Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity.

Authors:  Jeffrey J Babon; Nadia J Kershaw; James M Murphy; Leila N Varghese; Artem Laktyushin; Samuel N Young; Isabelle S Lucet; Raymond S Norton; Nicos A Nicola
Journal:  Immunity       Date:  2012-02-24       Impact factor: 31.745

Review 3.  The use of structural biology in Janus kinase targeted drug discovery.

Authors:  Nilda L Alicea-Velázquez; Titus J Boggon
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

4.  A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q/K539L.

Authors:  Kavitha Gnanasambandan; Andrew T Magis; Peter P Sayeski
Journal:  Mol Cell Biochem       Date:  2012-05-15       Impact factor: 3.842

Review 5.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

6.  Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection.

Authors:  Davide Eletto; Siobhan O Burns; Ivan Angulo; Vincent Plagnol; Kimberly C Gilmour; Frances Henriquez; James Curtis; Miguel Gaspar; Karolin Nowak; Vanessa Daza-Cajigal; Dinakantha Kumararatne; Rainer Doffinger; Adrian J Thrasher; Sergey Nejentsev
Journal:  Nat Commun       Date:  2016-12-23       Impact factor: 14.919

7.  Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.

Authors:  Michael R Marit; Manprit Chohan; Natasha Matthew; Kai Huang; Douglas A Kuntz; David R Rose; Dwayne L Barber
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.